ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0288 • ACR Convergence 2025

    Predictors and Characteristics of Objective Flares in Adult Dermatomyositis

    Didem Saygin1, York Wang2, Kathryn C. Fitzgerald3, Jemima Albayda4, Julie Paik5, Eleni Tiniakou6, Brittany L Adler2, Andrew Mammen7, Lisa Christopher-Stine4 and Chris Mecoli2, 1Rush University Medical Center, Chicago, IL, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, 4Johns Hopkins University, Baltimore, MD, 5Johns Hopkins Rheumatology, Baltimore, MD, 6UT Health Science Houston, Houston, TX, 7NIH, Bethesda, MD

    Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with a heterogenous clinical course. Flares often lead to increased morbidity, health care utilization, and reduced…
  • Abstract Number: 0068 • ACR Convergence 2025

    Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis

    Aryan Patel1, Osama Al Zoubi2 and Shiva Shahrara3, 1University of Illinois at Chicago, Chicago, 2University of Illinois at Chicago, Chicago, IL, 3University of Illinois, Chicago, IL

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1% of the global population, causing significant morbidity and disability. Fibroblast-like synoviocytes (FLS) are…
  • Abstract Number: 0280 • ACR Convergence 2025

    Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.

    Suchada Kaewin1, Cecilia Leijding2, Kristofer Andreasson2, Helene Alexanderson3, Stefano Gastaldello1, Ingrid Lundberg2 and Daniel C. Andersson2, 1Karolinska Institutet, inst fysiologi och farmakologi, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Dermatomyositis (DM) is a major subtype of idiopathic inflammatory myopathies (IIMs) and characterized by muscle weakness, systemic inflammation and cutaneous lesions. Expression of type…
  • Abstract Number: 0287 • ACR Convergence 2025

    Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies

    Daniel Alberto Carrillo-Vázquez1, Beatriz Alcalá-Carmona1, Jennifer Tiaré Balderas Miranda2, Yatzil Reyna Juárez3, María José Ostos Prado1, Samuel Govea-Peláez1, Nancy R Mejía Domínguez4, Guillermo Juárez Vega4, Karina Santana-De Anda1, Jiram Torres-Ruiz5 and Diana Gómez-Martín6, 1Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, 2Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, 3Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, 4Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Ciudad de México, Mexico, 6INCMNSZ, Mexico city, Federal District, Mexico

    Background/Purpose: Vasculopathic manifestations of idiopathic inflammatory myopathies (IIM) such as interstitial lung disease (ILD), calcinosis, skin ulcers, mechanic’s hands, are characterized by immune-mediated vascular damage.…
  • Abstract Number: 0192 • ACR Convergence 2025

    Digital Empowerment on Hold: Adoption Gaps in Prescribable Digital Health Applications – A National Cross-Sectional Study from Germany

    Phillip Kremer1, Daniel Fink2, Harriet Morf3, Hannah Labinsky4, Karolina Gente5, Peer Aries6, Martin Krusche1, Sebastian Kuhn7, Axel Hueber8 and Johannes Knitza9, 1Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Rheumazentrum Mittelhessen, Bad Endbach, Germany, 3Department of Medicine 3 - Rheumatology & Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 4University Hospital of Wuerzburg, Würzburg, Germany, 5Department of Internal Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-Wurttemberg, Germany, 6Department of Rheumatology, Immunologikum, Hamburg, Germany, 7Institute for Digital Medicine, University Hospital of Giessen and Marburg, Philipps University Marburg, Marburg, Germany, 8Klinikum Nuernberg, Nuernberg, Germany, 9Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany

    Background/Purpose: Rheumatic and musculoskeletal diseases (RMDs) are chronic conditions that require complex, multidisciplinary care. Since 2020, digital health applications (DiGAs) have been available for prescription…
  • Abstract Number: 0171 • ACR Convergence 2025

    The Association Between Short-Term Trajectory Of Atmospheric Particulate Matter 10 (PM10) Concentration And Hyperuricemia

    Sunggun Lee1, Minyoung Her1, Seong-HO Kim1, Yong-Gil Kim2 and Ji Seon Oh2, 1Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea

    Background/Purpose: The association between high atmospheric particulate matter concentration and gout flare has been reported1, but the causality and mechanism of this association remain unknown.…
  • Abstract Number: 0188 • ACR Convergence 2025

    Investigating Canadians’ information needs related to lupus: A Google Trends analysis of online search query data

    Taylor Williamson1, Emily Shantz1, Susan Elliott1, Christine Sperling2, Karen H. Costenbader3 and May Choi4, 1University of Waterloo, Waterloo, Canada, 2None, Calgary, Canada, 3Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 4University of Calgary, Calgary, AB, Canada

    Background/Purpose: A lack of knowledge surrounding SLE has been identified as a main challenge for patients, particularly those seeking a diagnosis or recently diagnosed. Subsequently,…
  • Abstract Number: 0022 • ACR Convergence 2025

    Genome-wide association study identifies novel genetic risk factors for rheumatoid arthritis-associated interstitial lung disease

    Austin Wheeler1, Thomas Riley2, Riku Takei3, Joshua Baker2, Yangyuna Yang1, Punyasha Roul4, Katherine Wysham5, Grant Cannon6, Gary Kunkel7, Gail Kerr8, Dana Ascherman9, Paul Monach10, Andreas Reimold11, Jill Poole1, Ted Mikuls1, Tony Merriman12 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Alabama at Birmingham, Birmingham, AL, 4UNMC, Omaha, NE, 5VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 6University of Utah and Salt Lake City VA, Salt Lake City, UT, 7University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 8Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 9University of Pittsburgh, Pittsburgh, PA, 10VA Boston Healthcare System, Boston, MA, 11Dallas VA Medical Center, Dallas, TX, 12University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: Interstitial lung disease (ILD) is clinically present in ~10% of individuals with RA. There is recognized overlap between RA-ILD and idiopathic pulmonary fibrosis (IPF)…
  • Abstract Number: 0286 • ACR Convergence 2025

    Anifrolumab For Treatment Of Refractory Juvenile Dermatomyositis In Adult Patients

    Connor Buechler1 and David Pearson2, 1University of Minnesota, Mendota Heights, MN, 2Department of Dermatology, University of Minnesota, Minneapolis, MN

    Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune connective tissue disorder with a chronic, relapsing course that can persist into adulthood. Current therapies exhibit widely variable…
  • Abstract Number: 0224 • ACR Convergence 2025

    Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis

    John Hickernell1 and Zineb Aouhab2, 1Loyola Univeristy Medical Center, Chicago, IL, 2Loyola University Medical Center, Oak Brook, IL

    Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) reduces mortality. The American College of Radiology, European Society of Cardiology/European Respiratory…
  • Abstract Number: 0261 • ACR Convergence 2025

    Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data

    Daphne Guinn1, Linchen He2, Yuru Ren1, Valeriy Korostyshevskiy1 and Robert Beckman1, 1Georgetown University, Washington, 2Novartis, East Hanover

    Background/Purpose: Basket trials group together participants who share a common biomarker or disease pathway across several diseases or phenotypes in a single clinical study. Such…
  • Abstract Number: 0290 • ACR Convergence 2025

    Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey

    Ezgi Sahin1, Omer Uludag2, yasemin yalcinkaya3, Bahar Artim Esen4, Ahmet Gul3 and Murat Inanc3, 1Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 2Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 3Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, 4Istanbul University, Istanbul, Istanbul, Turkey

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases characterized by muscle weakness, often involving other organs such as the skin, lungs, and heart. Defined…
  • Abstract Number: 0234 • ACR Convergence 2025

    Use of Corneal Confocal Microscopy to Assess Small Fiber Neuropathy in Patients with Sarcoidosis

    Philip Bucur1, Kelly Gwathmey2, Huzaefah Syed2, Aamer Syed2, Thomas Iden3, Neha Gupta2, Jessica McLaughlin2, Jordana Kron2, Ryan Canissario2, Shanshan Chen1, Hoda Gad4, Rayaz Malik4, Sai Patel2 and Vaishali Patel2, 1VCU Health, Richmond, VA, 2Virginia Commonwealth University Medical Center, Richmond, VA, 3Virginia Commonwealth University Medical Center, Richmond, 4Weill Cornell Medicine-Qatar, Doha, Qatar

    Background/Purpose: Small fiber neuropathy (SFN) is a common complication of sarcoidosis, affecting about one third of patients. The current gold standard for diagnosis combines patient…
  • Abstract Number: 0289 • ACR Convergence 2025

    Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures

    Didem Saygin1, Matthew Diller2, Varsha Surampudi3, Mark Bodkin3, Payam Farhadi4, Adam Schiffenbauer5, Audrey Kessel3, Chris Mecoli6, Rohit Aggarwal7, Helene Alexanderson8, Michelle Best9, Olivier Benveniste10, Hector Chinoy11, Brian Feldman12, Linda Kobert13, Manuel Lubinus14, Liza McCann15, Chester V. Oddis16, Nicolino Ruperto17, Jens Schmidt18, Victoria Werth19, Christie Bartels20, Hanna Kim21, Andrew Mammen22, Julie Paik23, Ellen M. Werner13, Ingrid de Groot24, Pedro Machado25, Susan Kim26, Tahseen Mozaffar27, Adam M Huber28, Angelo Ravelli29, Richard Scheuermann2 and Lisa Rider30, 1Rush University Medical Center, Chicago, IL, 2National Library of Medicine, National institutes of Health, Bethesda, MD, 3Social Scientific System Inc, a DLH holding company, Baltimore, MD, 4National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, 5National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD, 7University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, 8Karolinska University Hospital, Stockholm, Sweden, 9Cure JM Foundation, Lessburg, VA, 10Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, 11The University of Manchester, Manchester, United Kingdom, 12The Hospital for Sick Children, Toronto, ON, Canada, 13The Myositis Association, Columbia, MD, 14Myositis Support and Understanding, Lincoln, DE, 15Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 16University of Pittsburgh, Pittsburgh, PA, 17Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, 18Immanuel University Hospital Ruedersdorf, Brandenburg Medical School, Rudersdorf, Germany, 19University of Pennsylvania, Philadelphia, PA, 20University of Wisconsin School of Medicine and Public Health, Madison, WI, 21NIAMS, NIH, Bethesda, MD, 22NIH, Bethesda, MD, 23Johns Hopkins Rheumatology, Baltimore, MD, 24The Myositis Association, Rotterdam, Netherlands, 25University College London, London, United Kingdom, 26UCSF Benioff Children's Hospital, San Francisco, CA, 27University of California, Irvine, Orange, CA, 28IWK Grace Health Centre, Halifax, NS, Canada, 29IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, 30National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD

    Background/Purpose: Recent progress has been made in developing myositis outcome assessments, response and classification criteria, and consensus in the design and conduct of clinical trials…
  • Abstract Number: 0293 • ACR Convergence 2025

    Presence of Anti-cN-1A (Mup44, NT5c1A) IgG is Specific for Sporadic Inclusion Body Myositis

    Jackie Weiss1, Miriam Mende2, EunByul Cho3, Guo Shen3, Dmitry Karayev3, Allan L. Metzger3, Robert I. Morris3, Sabine L. Kramp2, Cornelia Dähnrich2 and Wolfgang Schlumberger2, 1EUROIMMUN US, Mountain Lakes, NJ, 2Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany, 3RDL Reference Laboratory Inc., Los Angeles, CA

    Background/Purpose: Sporadic inclusion body myositis (sIBM) is an autoimmune disease manifesting with muscle degeneration, inflammatory infiltrates and inclusion vacuoles. Diagnosis of sIBM is hampered by…
  • « Previous Page
  • 1
  • …
  • 75
  • 76
  • 77
  • 78
  • 79
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology